CEL-SCI Corporation, a clinical stage cancer immunotherapy company, has successfully closed its underwritten public offering of 2,000,000 shares of common stock, priced at $2.50 per share. The offering generated total gross proceeds of $5 million, prior to the deduction of underwriting discounts and other related expenses. The company has also granted underwriters a 45-day option to purchase an additional 190,000 shares to address over-allotments. The funds raised are intended to support the continued development of Multikine, as well as general corporate purposes and working capital. ThinkEquity served as the sole book-running manager for the offering.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。